TW321649B
(es)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
DE69613367T2
(de)
*
|
1995-04-27 |
2002-04-18 |
Astrazeneca Ab |
Chinazolin derivate
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
GB9624482D0
(en)
*
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
BR9707495A
(pt)
|
1996-02-13 |
1999-07-27 |
Zeneca Ltd |
Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
KR100489174B1
(ko)
|
1996-03-05 |
2005-09-30 |
제네카-파마 소시에떼아노님 |
4-아닐리노퀴나졸린유도체
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
WO1998033798A2
(en)
*
|
1997-02-05 |
1998-08-06 |
Warner Lambert Company |
Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
|
EP1806348A3
(en)
*
|
1997-02-05 |
2008-01-02 |
Warner-Lambert Company LLC |
Pyrido [2, 3 -d] pyrimidines and 4-amino-primidines as inhibitors of cellular proliferation
|
US6498163B1
(en)
|
1997-02-05 |
2002-12-24 |
Warner-Lambert Company |
Pyrido[2,3-D]pyrimidines and 4-aminopyrimidines as inhibitors of cellular proliferation
|
US5945422A
(en)
*
|
1997-02-05 |
1999-08-31 |
Warner-Lambert Company |
N-oxides of amino containing pyrido 2,3-D! pyrimidines
|
GB9716231D0
(en)
|
1997-07-31 |
1997-10-08 |
Amersham Int Ltd |
Base analogues
|
EP1801112A1
(en)
*
|
1998-05-26 |
2007-06-27 |
Warner-Lambert Company LLC |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyrimidines as inhibitors of cellular proliferation
|
US7501425B1
(en)
*
|
1998-05-26 |
2009-03-10 |
Warner Lambert Company |
Bicyclic pyrimidines and bicyclic 3,4-dihydropyprimidines as inhibitors of cellular proliferation
|
PL347432A1
(en)
*
|
1998-10-23 |
2002-04-08 |
Hoffmann La Roche |
Bicyclic nitrogen heterocycles
|
PL357502A1
(en)
|
1999-10-21 |
2004-07-26 |
F.Hoffmann-La Roche Ag |
Heteroalkylamino-substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
|
WO2001029041A1
(en)
|
1999-10-21 |
2001-04-26 |
F. Hoffmann-La Roche Ag |
Alkylamino substituted bicyclic nitrogen heterocycles as inhibitors of p38 protein kinase
|
AU769222B2
(en)
|
1999-11-05 |
2004-01-22 |
Genzyme Corporation |
Quinazoline derivatives as VEGF inhibitors
|
WO2001042243A2
(en)
*
|
1999-12-08 |
2001-06-14 |
Advanced Medicine, Inc. |
Protein kinase inhibitors
|
US20020002169A1
(en)
|
1999-12-08 |
2002-01-03 |
Griffin John H. |
Protein kinase inhibitors
|
JP2005507392A
(ja)
|
2000-08-04 |
2005-03-17 |
ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー |
2−(4−ピリジル)アミノ−6−ジアルキルオキシフェニルピリド〔2,3−d〕ピリミジン−7−オン類の製造方法
|
WO2002012237A2
(en)
|
2000-08-04 |
2002-02-14 |
Warner-Lambert Company |
Process for preparing 2-(4-pyridyl)amino-6-dialkyloxyphenyl-pyrido[2,3-d]pyrimidin-7-ones
|
US6518276B2
(en)
|
2000-08-31 |
2003-02-11 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (II)
|
JP4146721B2
(ja)
*
|
2000-08-31 |
2008-09-10 |
エフ.ホフマン−ラ ロシュ アーゲー |
7−オキソ−ピリドピリミジン類
|
EP1315726A1
(en)
*
|
2000-08-31 |
2003-06-04 |
F. Hoffmann-La Roche Ag |
7- oxo pyridopyrimidines as inhibitors of cellular proliferation
|
US6506749B2
(en)
|
2000-08-31 |
2003-01-14 |
Syntex (U.S.A.) Llc |
7-oxo-pyridopyrimidines (I)
|
CN100376571C
(zh)
*
|
2001-02-12 |
2008-03-26 |
霍夫曼-拉罗奇有限公司 |
6-取代的吡啶并嘧啶类化合物
|
WO2003057165A2
(en)
*
|
2002-01-04 |
2003-07-17 |
The Rockefeller University |
COMPOSITIONS AND METHODS FOR PREVENTION AND TREATMENT OF AMYLOID-β PEPTIDE-RELATED DISORDERS
|
OA12755A
(en)
|
2002-01-22 |
2006-07-03 |
Warner Lambert Co |
2-(pyridin-2-ylamino)-pyridoÄ2,3dÜpyrimidin-7-ones.
|
US6822097B1
(en)
*
|
2002-02-07 |
2004-11-23 |
Amgen, Inc. |
Compounds and methods of uses
|
US7196090B2
(en)
|
2002-07-25 |
2007-03-27 |
Warner-Lambert Company |
Kinase inhibitors
|
WO2004014907A1
(en)
|
2002-08-06 |
2004-02-19 |
F. Hoffmann-La Roche Ag |
6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
|
PL377795A1
(pl)
*
|
2002-11-28 |
2006-02-20 |
Schering Aktiengesellschaft |
Pirymidyny będące inhibitorami Chk, Pdk i Akt, sposób ich wytwarzania oraz ich zastosowanie jako środków farmaceutycznych
|
CN100420687C
(zh)
*
|
2002-12-20 |
2008-09-24 |
霍夫曼-拉罗奇有限公司 |
作为选择性kdr和fgfr抑制剂的吡啶并[2,3-d]嘧啶衍生物
|
US7098332B2
(en)
*
|
2002-12-20 |
2006-08-29 |
Hoffmann-La Roche Inc. |
5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
|
US6861422B2
(en)
|
2003-02-26 |
2005-03-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions
|
US7160888B2
(en)
*
|
2003-08-22 |
2007-01-09 |
Warner Lambert Company Llc |
[1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
|
AU2004279427B2
(en)
*
|
2003-10-08 |
2008-07-03 |
Irm Llc |
Compounds and compositions as protein kinase inhibitors
|
RU2348632C2
(ru)
|
2003-11-13 |
2009-03-10 |
Ф.Хоффманн-Ля Рош Аг |
Гидроксиалкилзамещенные пиридо-7-пиримидин-7-оны
|
JP2007523151A
(ja)
*
|
2004-02-18 |
2007-08-16 |
ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー |
2−(ピリジン−3−イルアミノ)−ピリド[2,3−d]ピリミジン−7−オン
|
WO2005105097A2
(en)
*
|
2004-04-28 |
2005-11-10 |
Gpc Biotech Ag |
Pyridopyrimidines for treating inflammatory and other diseases
|
DE102004029784A1
(de)
|
2004-06-21 |
2006-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004033670A1
(de)
|
2004-07-09 |
2006-02-02 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Pyridodihydropyrazinone, Verfahren zu Ihrer Herstellung und Ihre Verwendung als Arzneimittel
|
FR2873118B1
(fr)
|
2004-07-15 |
2007-11-23 |
Sanofi Synthelabo |
Derives de pyrido-pyrimidine, leur application en therapeutique
|
US7759485B2
(en)
|
2004-08-14 |
2010-07-20 |
Boehringer Ingelheim International Gmbh |
Process for the manufacture of dihydropteridinones
|
US20060058311A1
(en)
|
2004-08-14 |
2006-03-16 |
Boehringer Ingelheim International Gmbh |
Combinations for the treatment of diseases involving cell proliferation
|
US7728134B2
(en)
|
2004-08-14 |
2010-06-01 |
Boehringer Ingelheim International Gmbh |
Hydrates and polymorphs of 4[[(7R)-8-cyclopentyl-7-ethyl-5,6,7,8-tetrahydro-5-methyl-6-oxo-2-pteridinyl]amino]-3-methoxy-N-(1-methyl-4-piperidinyl)-benzamide, process for their manufacture and their use as medicament
|
US20060035903A1
(en)
|
2004-08-14 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Storage stable perfusion solution for dihydropteridinones
|
US20060074088A1
(en)
|
2004-08-14 |
2006-04-06 |
Boehringer Ingelheim International Gmbh |
Dihydropteridinones for the treatment of cancer diseases
|
EP1630163A1
(de)
|
2004-08-25 |
2006-03-01 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Dihydropteridinonderivative, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
EP1786817A1
(de)
*
|
2004-08-26 |
2007-05-23 |
Boehringer Ingelheim International GmbH |
Pteridinone als plk (polo like kinase) inhibitoren
|
DE102004058337A1
(de)
|
2004-12-02 |
2006-06-14 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten
|
FR2887882B1
(fr)
|
2005-07-01 |
2007-09-07 |
Sanofi Aventis Sa |
Derives de pyrido[2,3-d] pyrimidine, leur preparation, leur application en therapeutique
|
CN101300258A
(zh)
*
|
2005-09-14 |
2008-11-05 |
詹森药业有限公司 |
作为c-fms激酶抑制剂的5-氧代-5,8-二氢-吡啶并-嘧啶类
|
US7642270B2
(en)
|
2005-09-14 |
2010-01-05 |
Janssen Pharmaceutica N.V. |
5-oxo-5,8-dihydro-pyrido-pyrimidine as inhibitors of c-fms kinase
|
TW200800983A
(en)
|
2005-09-14 |
2008-01-01 |
Janssen Pharmaceutica Nv |
5-oxo-5,8-dihydro-pyrido-pyrimidines as inhibitors of C-FMS kinase
|
JP5480503B2
(ja)
*
|
2005-10-07 |
2014-04-23 |
エクセリクシス, インク. |
PI3Kαのピリドピリミジノン型阻害剤
|
KR101492795B1
(ko)
*
|
2005-10-07 |
2015-02-13 |
엑셀리시스, 인코포레이티드 |
PI3Kα의 피리도피리미디논 억제제
|
FR2896246B1
(fr)
*
|
2006-01-13 |
2008-08-15 |
Sanofi Aventis Sa |
Derives de pyrido-pyrimidone, leur preparation, leur application en therapeutique.
|
AU2007211684A1
(en)
|
2006-01-31 |
2007-08-09 |
F. Hoffmann-La Roche Ag |
7H-pyrido[3,4-d]pyrimidin-8-ones, their manufacture and use as protein kinase inhibitors
|
US7439358B2
(en)
|
2006-02-08 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Specific salt, anhydrous and crystalline form of a dihydropteridione derivative
|
JP2010500283A
(ja)
*
|
2006-05-31 |
2010-01-07 |
ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー |
チロシンキナーゼ阻害剤を用いて炎症性疾患を治療する方法
|
EA016388B1
(ru)
|
2006-09-15 |
2012-04-30 |
Пфайзер Продактс Инк. |
Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов
|
EP1914234A1
(en)
|
2006-10-16 |
2008-04-23 |
GPC Biotech Inc. |
Pyrido[2,3-d]pyrimidines and their use as kinase inhibitors
|
JO2985B1
(ar)
|
2006-12-20 |
2016-09-05 |
Takeda Pharmaceuticals Co |
مثبطات كينازmapk/erk
|
FR2910813B1
(fr)
|
2006-12-28 |
2009-02-06 |
Sanofi Aventis Sa |
Nouvelle utilisation therapeutique pour le traitement des leucemies
|
WO2008127678A1
(en)
*
|
2007-04-11 |
2008-10-23 |
Exelixis, Inc. |
Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
|
WO2008127712A1
(en)
*
|
2007-04-11 |
2008-10-23 |
Exelixis, Inc. |
Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
|
JP5261487B2
(ja)
|
2007-08-03 |
2013-08-14 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ジヒドロプテリジノン誘導体の結晶形
|
EP2112150B1
(en)
|
2008-04-22 |
2013-10-16 |
Forma Therapeutics, Inc. |
Improved raf inhibitors
|
AR073524A1
(es)
|
2008-09-30 |
2010-11-10 |
Exelixis Inc |
Piridopirimidinonas inhibidores de pi3k a y m tor
|
WO2010071846A2
(en)
*
|
2008-12-19 |
2010-06-24 |
Afraxis, Inc. |
Compounds for treating neuropsychiatric conditions
|
SG178279A1
(en)
|
2009-08-05 |
2012-03-29 |
Intra Cellular Therapies Inc |
Novel regulatory proteins and inhibitors
|
KR20120104200A
(ko)
*
|
2009-10-09 |
2012-09-20 |
아프락시스 인코포레이티드 |
Cns 장애의 치료를 위한 8에틸6(아릴)피리도[2,3d]피리미딘7(8h)온
|
FR2955109B1
(fr)
|
2010-01-08 |
2012-09-07 |
Sanofi Aventis |
Derives de 5-oxo-5,8-dihydro-pyrido[2, 3-d]pyrimidine, leur preparation et leur application en therapeutique
|
AR080151A1
(es)
|
2010-02-09 |
2012-03-14 |
Exelixis Inc |
Metodos para tratar cancer usando inhibidores de piridopirimidinona de pi 3k y mtor en combinacion con inhibidores de autofagia
|
US8546566B2
(en)
|
2010-10-12 |
2013-10-01 |
Boehringer Ingelheim International Gmbh |
Process for manufacturing dihydropteridinones and intermediates thereof
|
US9358233B2
(en)
|
2010-11-29 |
2016-06-07 |
Boehringer Ingelheim International Gmbh |
Method for treating acute myeloid leukemia
|
SG10201913982WA
(en)
|
2011-03-04 |
2020-03-30 |
Newgen Therapeutics Inc |
Alkyne Substituted Quinazoline Compound And Methods Of Use
|
WO2013043232A2
(en)
*
|
2011-04-08 |
2013-03-28 |
Afraxis, Inc. |
8-ethyl-6-(aryl)pyrido [2,3-d]pyrimidin-7(8h) -ones for the treatment of nervous system disorders and cancer
|
US9370535B2
(en)
|
2011-05-17 |
2016-06-21 |
Boehringer Ingelheim International Gmbh |
Method for treatment of advanced solid tumors
|
US9951088B2
(en)
*
|
2012-05-09 |
2018-04-24 |
Sunovion Pharmaceuticals Inc. |
D2 receptor modulators and methods of use thereof in the treatment of diseases and disorders
|
EP2872491B1
(en)
*
|
2012-07-11 |
2021-05-05 |
Blueprint Medicines Corporation |
Inhibitors of the fibroblast growth factor receptor
|
AU2013323736A1
(en)
|
2012-09-26 |
2015-04-09 |
Mannkind Corporation |
Multiple kinase pathway inhibitors
|
WO2015011236A1
(en)
|
2013-07-26 |
2015-01-29 |
Boehringer Ingelheim International Gmbh |
Treatment of myelodysplastic syndrome
|
HRP20220840T1
(hr)
|
2013-10-25 |
2022-10-14 |
Blueprint Medicines Corporation |
Inhibitori receptora faktora rasta fibroblasta
|
US9867831B2
(en)
|
2014-10-01 |
2018-01-16 |
Boehringer Ingelheim International Gmbh |
Combination treatment of acute myeloid leukemia and myelodysplastic syndrome
|
CN106749173A
(zh)
*
|
2016-11-25 |
2017-05-31 |
吉林化工学院 |
一种嘧啶联吡啶类化合物的制备方法
|
US11174255B2
(en)
|
2017-05-15 |
2021-11-16 |
University Of Houston System |
Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases
|
JP2022533182A
(ja)
*
|
2019-05-16 |
2022-07-21 |
ユニバーシティー オブ ヒューストン システム |
タンパク質キナーゼ阻害剤ならびに疾患および状態の治療のためのその使用
|
KR102329720B1
(ko)
*
|
2019-08-30 |
2021-11-23 |
한국과학기술연구원 |
단백질 키나아제 저해 활성을 갖는 신규한 피리미도[4,5-d]피리미딘-2-온 유도체
|
US11697648B2
(en)
|
2019-11-26 |
2023-07-11 |
Theravance Biopharma R&D Ip, Llc |
Fused pyrimidine pyridinone compounds as JAK inhibitors
|
WO2023177356A2
(en)
*
|
2022-03-18 |
2023-09-21 |
Engine Biosciences Pte. Ltd. |
Compounds and method for pkmyt1 inhibition
|